Kangrong Li, Pan Gong, Yongbin Zhang, Minji Liu, Zinan Zhang, Xiaoyu Yu, Mingmei Ye, Li Tian
{"title":"内脏脂肪组织对克罗恩病抗肿瘤坏死因子-α的影响。","authors":"Kangrong Li, Pan Gong, Yongbin Zhang, Minji Liu, Zinan Zhang, Xiaoyu Yu, Mingmei Ye, Li Tian","doi":"10.1177/17562848231171962","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>It remains unclear whether visceral adipose tissue (VAT) can predict the response of patients with Crohn's disease (CD) to anti-tumour necrosis factor-α (anti-TNF-α) therapy.</p><p><strong>Objectives: </strong>This study aimed to investigate whether VAT predicts the efficacy of infliximab (IFX) for different sites of CD and its relationship with serum TNF-α levels and IFX serum trough concentration.</p><p><strong>Design: </strong>This is a multicentre retrospective study.</p><p><strong>Methods: </strong>Patients with CD treated with IFX from January 2014 to January 2021 were included. The perimeter of the visceral adipose area was obtained by a Computed Tomography (CT) scan. Participants were classified according to the lesion site (L<sub>1</sub>, L<sub>2</sub>, and L<sub>3</sub>) and visceral fat area. The participants were divided into colon-uninvolved non-visceral obesity (L<sub>1</sub>-VAT<sub>L</sub>), colon-uninvolved visceral obesity (L<sub>1</sub>-VAT<sub>H</sub>), colon-involved non-visceral obesity (L<sub>2</sub> + L<sub>3</sub>-VAT<sub>L</sub>), and colon involved visceral obesity (L<sub>2</sub> + L<sub>3</sub>-VAT<sub>H</sub>) groups. The end points of this study were set as disease remission status at 6 and 12 months.</p><p><strong>Results: </strong>The final cohort included 140 patients. Regarding efficacy at 6 and 12 months, there was a significant difference between L<sub>1</sub>-VAT<sub>L</sub> (73.8% <i>versus</i> 36.8%, <i>p</i> = 0.006) and L<sub>1</sub>-VAT<sub>H</sub> (81.0% <i>versus</i> 47.4%, <i>p</i> = 0.008) groups. In the analysis of serum TNF-α levels and IFX serum trough concentrations, there was a significant difference between L<sub>1</sub>-VAT<sub>L</sub> and L<sub>1</sub>-VAT<sub>H</sub> (59.5 pg/mL <i>versus</i> 236.0 pg/mL, <i>p</i><sub>TNF-α</sub> = 0.006), (10.0 μg/mL <i>versus</i> 0.4 μg/mL, <i>p</i><sub>IFX</sub> = 0.000), and L<sub>1</sub>-VAT<sub>H</sub> and L<sub>2</sub> + L<sub>3</sub>-VAT<sub>H</sub> (78.7 pg/mL <i>versus</i> 118.6 pg/mL, <i>p</i><sub>TNF-α</sub> = 0.031), (0.4 μg/mL <i>versus</i> 6.40 μg/mL, <i>p</i><sub>IFX</sub> = 0.017).</p><p><strong>Conclusion: </strong>In L<sub>1</sub> patients, the VAT level predicted the efficacy of IFX, with high VAT values indicating poor efficacy. The VAT level may be a useful radiological marker to predict the efficacy of IFX in patients with various types of CD.</p>","PeriodicalId":23022,"journal":{"name":"Therapeutic Advances in Gastroenterology","volume":"16 ","pages":"17562848231171962"},"PeriodicalIF":4.2000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c1/46/10.1177_17562848231171962.PMC10164858.pdf","citationCount":"0","resultStr":"{\"title\":\"Effects of visceral adipose tissue on anti-tumour necrosis factor-α in Crohn's disease.\",\"authors\":\"Kangrong Li, Pan Gong, Yongbin Zhang, Minji Liu, Zinan Zhang, Xiaoyu Yu, Mingmei Ye, Li Tian\",\"doi\":\"10.1177/17562848231171962\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>It remains unclear whether visceral adipose tissue (VAT) can predict the response of patients with Crohn's disease (CD) to anti-tumour necrosis factor-α (anti-TNF-α) therapy.</p><p><strong>Objectives: </strong>This study aimed to investigate whether VAT predicts the efficacy of infliximab (IFX) for different sites of CD and its relationship with serum TNF-α levels and IFX serum trough concentration.</p><p><strong>Design: </strong>This is a multicentre retrospective study.</p><p><strong>Methods: </strong>Patients with CD treated with IFX from January 2014 to January 2021 were included. The perimeter of the visceral adipose area was obtained by a Computed Tomography (CT) scan. Participants were classified according to the lesion site (L<sub>1</sub>, L<sub>2</sub>, and L<sub>3</sub>) and visceral fat area. The participants were divided into colon-uninvolved non-visceral obesity (L<sub>1</sub>-VAT<sub>L</sub>), colon-uninvolved visceral obesity (L<sub>1</sub>-VAT<sub>H</sub>), colon-involved non-visceral obesity (L<sub>2</sub> + L<sub>3</sub>-VAT<sub>L</sub>), and colon involved visceral obesity (L<sub>2</sub> + L<sub>3</sub>-VAT<sub>H</sub>) groups. The end points of this study were set as disease remission status at 6 and 12 months.</p><p><strong>Results: </strong>The final cohort included 140 patients. Regarding efficacy at 6 and 12 months, there was a significant difference between L<sub>1</sub>-VAT<sub>L</sub> (73.8% <i>versus</i> 36.8%, <i>p</i> = 0.006) and L<sub>1</sub>-VAT<sub>H</sub> (81.0% <i>versus</i> 47.4%, <i>p</i> = 0.008) groups. In the analysis of serum TNF-α levels and IFX serum trough concentrations, there was a significant difference between L<sub>1</sub>-VAT<sub>L</sub> and L<sub>1</sub>-VAT<sub>H</sub> (59.5 pg/mL <i>versus</i> 236.0 pg/mL, <i>p</i><sub>TNF-α</sub> = 0.006), (10.0 μg/mL <i>versus</i> 0.4 μg/mL, <i>p</i><sub>IFX</sub> = 0.000), and L<sub>1</sub>-VAT<sub>H</sub> and L<sub>2</sub> + L<sub>3</sub>-VAT<sub>H</sub> (78.7 pg/mL <i>versus</i> 118.6 pg/mL, <i>p</i><sub>TNF-α</sub> = 0.031), (0.4 μg/mL <i>versus</i> 6.40 μg/mL, <i>p</i><sub>IFX</sub> = 0.017).</p><p><strong>Conclusion: </strong>In L<sub>1</sub> patients, the VAT level predicted the efficacy of IFX, with high VAT values indicating poor efficacy. The VAT level may be a useful radiological marker to predict the efficacy of IFX in patients with various types of CD.</p>\",\"PeriodicalId\":23022,\"journal\":{\"name\":\"Therapeutic Advances in Gastroenterology\",\"volume\":\"16 \",\"pages\":\"17562848231171962\"},\"PeriodicalIF\":4.2000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c1/46/10.1177_17562848231171962.PMC10164858.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic Advances in Gastroenterology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/17562848231171962\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17562848231171962","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Effects of visceral adipose tissue on anti-tumour necrosis factor-α in Crohn's disease.
Background: It remains unclear whether visceral adipose tissue (VAT) can predict the response of patients with Crohn's disease (CD) to anti-tumour necrosis factor-α (anti-TNF-α) therapy.
Objectives: This study aimed to investigate whether VAT predicts the efficacy of infliximab (IFX) for different sites of CD and its relationship with serum TNF-α levels and IFX serum trough concentration.
Design: This is a multicentre retrospective study.
Methods: Patients with CD treated with IFX from January 2014 to January 2021 were included. The perimeter of the visceral adipose area was obtained by a Computed Tomography (CT) scan. Participants were classified according to the lesion site (L1, L2, and L3) and visceral fat area. The participants were divided into colon-uninvolved non-visceral obesity (L1-VATL), colon-uninvolved visceral obesity (L1-VATH), colon-involved non-visceral obesity (L2 + L3-VATL), and colon involved visceral obesity (L2 + L3-VATH) groups. The end points of this study were set as disease remission status at 6 and 12 months.
Results: The final cohort included 140 patients. Regarding efficacy at 6 and 12 months, there was a significant difference between L1-VATL (73.8% versus 36.8%, p = 0.006) and L1-VATH (81.0% versus 47.4%, p = 0.008) groups. In the analysis of serum TNF-α levels and IFX serum trough concentrations, there was a significant difference between L1-VATL and L1-VATH (59.5 pg/mL versus 236.0 pg/mL, pTNF-α = 0.006), (10.0 μg/mL versus 0.4 μg/mL, pIFX = 0.000), and L1-VATH and L2 + L3-VATH (78.7 pg/mL versus 118.6 pg/mL, pTNF-α = 0.031), (0.4 μg/mL versus 6.40 μg/mL, pIFX = 0.017).
Conclusion: In L1 patients, the VAT level predicted the efficacy of IFX, with high VAT values indicating poor efficacy. The VAT level may be a useful radiological marker to predict the efficacy of IFX in patients with various types of CD.
期刊介绍：
Therapeutic Advances in Gastroenterology is an open access journal which delivers the highest quality peer-reviewed original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of gastrointestinal and hepatic disorders. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in gastroenterology and related disciplines, providing an online forum for rapid dissemination of recent research and perspectives in this area.
The editors welcome original research articles across all areas of gastroenterology and hepatology.
The journal publishes original research articles and review articles primarily. Original research manuscripts may include laboratory, animal or human/clinical studies – all phases. Letters to the Editor and Case Reports will also be considered.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
